Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome p-450 polymorphisms and response to clopidogrel.

The New England journal of medicine - 22 Jan 2009

Mega Jessica L, Close Sandra L, Wiviott Stephen D, Shen Lei, Hockett Richard D, Brandt John T, Walker Joseph R, Antman Elliott M, Macias William, Braunwald Eugene, Sabatine Marc S

Abstract excerpt

BACKGROUND: Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. METHODS: We tested the association between functional genetic variants in CYP genes, plasma concentrations of active drug metabolite, and platelet inhibition in response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Acute Coronary Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angioplasty, Balloon, Coronary

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Randomized Controlled Trials as Topic

Share to Stents

Share to Ticlopidine

Source

Identifiers

PMID: 19106084
DOI: 10.1056/NEJMoa0809171

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome p-450 polymorphisms and response to clopidogrel.PMID 19106084Read ↗

Pharmacogenetics of clopidogrel.Semantic proximity Read ↗

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.Semantic proximity Read ↗

Recent advances in the pharmacogenetics of clopidogrel.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response.Semantic proximity Read ↗

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.Semantic proximity Read ↗

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

Clopidogrel and the Reduced-Function CYP2C19 Genetic VariantSemantic proximity Read ↗

Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment.Semantic proximity Read ↗

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.Semantic proximity Read ↗

Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.